NeuroScientific Biopharmaceuticals : Investor Webinar Presentation

ASX ANNOUNCEMENT 18 NOVEMBER 2021

For personal use only

INVESTOR WEBINAR PRESENTATION

NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) ("NeuroScientific" or "the company") is pleased to advise shareholders and investors that the Company will be presenting as part of the free Broker Briefing Investor Webinar to be held on Thursday 18 November 2021, 11:30am AEST / 8:30am AWST.

DATE: 18 November 2021

TIME: 11:30am AEST / 8:30am AWST

PRESENTER: Dr Alexandra Andrews, PhD - Director of Operations

WEBINAR LINK:https://zoom.us/webinar/register/WN_yeFPaaH-RuqlDd8Rmg2Uqg

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:
Matthew Liddelow	Lucas Robinson
CEO and Managing Director	Investor Relations
[e-mail]	Corporate Storytime
+ 61 8 6382 1805	[e-mail]
	+ 61 408 228 889

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide- based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinBTM, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinBTM. For more information, please visit www.neuroscientific.com

About EmtinBTM

EmtinBTM is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinBTM is modelled on a specific

NeuroScientific Biopharmaceuticals Ltd	www.neuroscientific.com
ABN: 13 102 832 995	[e-mail]
Suite 5, 85 Forrest Street, Cottesloe WA 6011	[e-mail]

For personal use only

active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury.

Our preclinical research has established that EmtinBTM is highly specific and selective for its target receptor, safe and well tolerated at high concentrations, and is able to penetrate the blood brain barrier. A series of Phase I clinical studies will be conducted to establish the safety profile of EmtinBTM in humans.

NeuroScientific Biopharmaceuticals Ltd	www.neuroscientific.com
ABN: 13 102 832 995	[e-mail]
Suite 5, 85 Forrest Street, Cottesloe WA 6011	[e-mail]

ersonal use only

N OV E L D R U G T H E R A P I E S F O R N E U R O D EG E N E R AT I V E C O N D I T I O N S

C o m p a n y P r e s e n t a t i o n

N o v e m b e r 2 0 2 1

ersonal use only

DISCLAIMER

The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd ("NeuroScientific", or "the Company"). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Further information is available upon request.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside NeuroScientific's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and NeuroScientific's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by NeuroScientific. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2

COMPANY SNAPSHOT

only		 Alzheimer's disease - global prevalence 55M¹, high unmet need
NOVEL LEAD COMPOUND		Multiple Sclerosis - US$27 billion treatment market ², unmet need for progressive MS
		Glaucoma - 76M global prevalence³, 2nd lead cause of blindness
		EmtinB™ - potential first in-class therapeutic for neurodegenerative conditions
ADDRESSING UNMET NEED IN		Potential disease modifying therapeutic
use	NEURODEGENERATION		Low potential for off-target effects
	 >40 studies completed to date
	SUBSTANTIAL SAFETY &
ersonal		Preclinical efficacy data in models of Alzheimer's disease, Multiple Sclerosis, Glaucoma
EFFICACY DATA		and Spinal Cord Injury.
	 Large body of published literature to support MOA
WELL FUNDED FOR PHASE 1	 Clinical studies in 2022 - First in Human Phase 1 for Neurology indications and First in
	Patient for Phase 1 for glaucoma
	PROGRAMS	
	$12.3M cash on hand

¹ World Health Organization - Dementia Factsheet September 2021 | ² fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-	3
100386 | ³ The Lancet Global Health Commission on Global Eye Health 2020